Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.34 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064683 | 0.89 | RAB9A (0.40) | ALDH1A1MAPTRXFP1HTTL3MBTL1 | |
| SCHEMBL20064757 | 0.85 | MCL1 (0.46) | ALDH1A1MAPTMCL1THRBRXFP1 | |
| SCHEMBL18198351 | 0.83 | MCL1 (0.36) | ALDH1A1MAPTMCL1TP53KDM4E | |
| SCHEMBL20064782 | 0.83 | KDM4E (0.48) | ALDH1A1SIRT5MAPTHTTTP53 | |
| SCHEMBL20064800 | 0.82 | KDM4E (0.35) | ALDH1A1MAPTHTTTP53KDM4E | |
| SCHEMBL20065127 | 0.82 | ALDH1A1 (0.38) | ALDH1A1SIRT5MAPTAKR1C3AKR1C2 | |
| SCHEMBL20064762 | 0.82 | ADORA2A (0.42) | ALDH1A1MAPTTP53KDM4E | |
| SCHEMBL18198326 | 0.82 | KDM4E (0.36) | ALDH1A1MAPTKDM4E | |
| SCHEMBL23953691 | 0.81 | AR (0.33) | ALDH1A1MAPTTHRBHTT | |
| SCHEMBL20064857 | 0.81 | HPGD (0.44) | ALDH1A1MAPTHTTTP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | ALDH1A1 3193/4885SIRT5 73/4885MAPT 3325/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | ALDH1A1 3193/4885SIRT5 73/4885MAPT 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.